Diffuse alveolar damage in nonresolving ARDS provides support for prolonged glucocorticoid treatment

Affiliations

¹ Division of Pulmonary, Critical Care, and Sleep Medicine, Departments of Medicine, Memphis Veterans Affairs Medical Center, Memphis, TN, USA, gmeduri@uthsc.edu.

Comment

Gianfranco Umberto Meduri. Intensive Care Med. 2015 Jun.

. 2015 Jun;41(6):1164-5.

doi: 10.1007/s00134-015-3797-y. Epub 2015 May 14.

¹ Division of Pulmonary, Critical Care, and Sleep Medicine, Departments of Medicine, Memphis Veterans Affairs Medical Center, Memphis, TN, USA, gmeduri@uthsc.edu.

No abstract available

Comment in

DAD in nonresolving ARDS provides support for prolonged glucocorticoid treatment: a rebuttal.
Guerin C. Guerin C. Intensive Care Med. 2015 Jun;41(6):1166-7. doi: 10.1007/s00134-015-3813-2. Epub 2015 Apr 25. Intensive Care Med. 2015. PMID: 25910430 No abstract available.

Open lung biopsy in nonresolving ARDS frequently identifies diffuse alveolar damage regardless of the severity stage and may have implications for patient management.
Guerin C, Bayle F, Leray V, Debord S, Stoian A, Yonis H, Roudaut JB, Bourdin G, Devouassoux-Shisheboran M, Bucher E, Ayzac L, Lantuejoul S, Philipponnet C, Kemeny JL, Souweine B, Richard JC. Guerin C, et al. Intensive Care Med. 2015 Feb;41(2):222-30. doi: 10.1007/s00134-014-3583-2. Epub 2014 Dec 5. Intensive Care Med. 2015. PMID: 25476984